# EDGAR Filing Document

**Accession Number:** 0001812360
**File Stem:** 0001493152-26-025636
**Filing Date:** 2026-5
**Character Count:** 18487
**Document Hash:** eacb282a41d202cc4fda7f248ef43b63
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-025636.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001493152-26-025636

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 49

**CONFORMED PERIOD OF REPORT**: 20260527

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260528

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FOXO TECHNOLOGIES INC.
- **CENTRAL INDEX KEY:** 0001812360
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 851050265
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39783
- **FILM NUMBER:** 261037278

**BUSINESS ADDRESS:**
- **STREET 1:** 477 SOUTH ROSEMARY AVENUE
- **STREET 2:** SUITE 224
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33401
- **BUSINESS PHONE:** (612) 800-0059

**MAIL ADDRESS:**
- **STREET 1:** 477 SOUTH ROSEMARY AVENUE
- **STREET 2:** SUITE 224
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33401

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Delwinds Insurance Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200518

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date Earliest Event Reported): May 27, 2026**

**FOXO TECHNOLOGIES INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| Delaware | 001-39783 | 85-1050265 |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| 477 South Rosemary Avenue<br> Suite 224<br> West Palm Beach, FL | 33401 |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

(612) 800-0059

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **N/A** |  |  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01** **Entry Into a Material Definitive Agreement.**

On May 27, 2026, FOXO Technologies Inc. (the "**Company**"), together with its wholly-owned subsidiary, FOXO Labs, Inc. ("**FLI**"), entered into a Strategic Technology License Agreement (the "**Agreement**") with Jon R. Sabes, the Company's founder, and LongevityFP Technologies, LLC, a Minnesota limited liability company controlled by Mr. Sabes ("**LongevityFP Technologies**").

The material terms of the Agreement are as follows:

(i) *License*. The Company and FLI granted LongevityFP Technologies an exclusive, worldwide license to commercialize the Company's epigenetics intellectual property portfolio, including two issued U.S. patents (U.S. Patent Nos. 11,795,495 and 11,817,214), a 13,000+ individual epigenetic dataset, proprietary machine learning models and algorithms, and related work product and arrangements (collectively, the "**Licensed IP**").

(ii) *Royalty*. LongevityFP Technologies will pay the Company a royalty equal to 3% of net revenues derived from commercialization of the Licensed IP, subject to an aggregate cap of $1,300,000.

(iii) *Acquisition Option*. LongevityFP Technologies received an exclusive, irrevocable ten-year option to acquire majority ownership of FLI. Upon a "Track A" exercise, LongevityFP Technologies acquires 100% of FLI and issues the Company a preferred membership interest representing 40% of LongevityFP Technologies's fully diluted common equity. Upon a "Track B" exercise, FLI issues LongevityFP Technologies 60% of FLI's fully diluted equity, with the Company retaining 40%.

(iv) *IP Retention*. The Company retains ownership of FLI and the Licensed IP throughout the license period.

(v) *Mutual Releases*. The Agreement includes mutual releases between the Company and Mr. Sabes and resolves all prior matters between the parties.

The foregoing description is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated into this Item 1.01 by reference.

**Item 7.01 Regulation FD Disclosure.**

On May 28, 2026, the Company issued a joint press release announcing its entry into the Strategic Technology License Agreement with Mr. Jon R. Sabes and LongevityFP Technologies, LLC, as described under Item 1.01 above. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibit hereto, is material or that the dissemination of such information is required by Regulation FD.

**<u>Cautionary Statement Regarding Forward-Looking Statements</u>**

This Current Report on Form 8-K contains "forward-looking statements." Any statements contained in this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "if," "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These forward-looking statements are based on information currently available to the Company's management as well as estimates and assumptions made by its management and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company's or its industry's actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and the Company does not undertake an obligation to update these forward-looking statements after such date.

**Item 9.01** **Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description of Exhibit** |
| 10.1 | [Strategic Technology License Agreement, dated as of May 27, 2026, by and among FOXO Technologies Inc., FOXO Labs, Inc., Jon R. Sabes, and LongevityFP Technologies, LLC (Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally omitted materials to the SEC upon request.)](ex10-1.htm) |
| 99.1 | [Joint Press Release dated May 28, 2026](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **FOXO Technologies Inc.** | **FOXO Technologies Inc.** |
| Date: May 28, 2026 | By: | */s/ Seamus Lagan* |
|  | Name: | Seamus Lagan |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**Certain schedules and exhibits to this Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The omitted schedules and exhibits are not material and would not contain information material to investors. The registrant agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule or exhibit upon request.**

![](ex10-1_001.jpg)

![](ex10-1_002.jpg)

![](ex10-1_003.jpg)

![](ex10-1_004.jpg)

![](ex10-1_005.jpg)

![](ex10-1_006.jpg)

![](ex10-1_007.jpg)

![](ex10-1_008.jpg)

![](ex10-1_009.jpg)

![](ex10-1_010.jpg)

![](ex10-1_011.jpg)

![](ex10-1_012.jpg)

![](ex10-1_013.jpg)

![](ex10-1_014.jpg)

![](ex10-1_015.jpg)

![](ex10-1_016.jpg)

![](ex10-1_017.jpg)

![](ex10-1_018.jpg)

![](ex10-1_019.jpg)

![](ex10-1_020.jpg)

![](ex10-1_021.jpg)

![](ex10-1_022.jpg)

![](ex10-1_023.jpg)

![](ex10-1_024.jpg)

![](ex10-1_025.jpg)

![](ex10-1_026.jpg)

![](ex10-1_027.jpg)

![](ex10-1_028.jpg)

![](ex10-1_029.jpg)

![](ex10-1_030.jpg)

![](ex10-1_031.jpg)

![](ex10-1_032.jpg)

![](ex10-1_033.jpg)

![](ex10-1_034.jpg)

![](ex10-1_035.jpg)

![](ex10-1_036.jpg)

## Exhibit 99.1

**Exhibit 99.1**

**FOXO TECHNOLOGIES, INC., FORMS STRATEGIC PARTNERSHIP WITH LONGEVITYFP TECHNOLOGIES, LLC. TO COMMERCIALIZE FOXO'S EPIGENETICS TECHNOLOGY**

WEST PALM BEACH, FL and MINNETONKA, MN, May 28, 2026 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (OTC: FOXO) (the "Company") and LongevityFP Technologies, LLC. ("LFP") today jointly announced a strategic partnership to commercialize the Company's pioneering epigenetics technology. The partnership is in the form of an exclusive license agreement (the "Agreement") whereby the Company's epigenetics-related technology including the Company's two patents and related intellectual property, will be licensed to LFP.

LongevityFP Technologies, LLC., is owned and operated by Jon R. Sabes, the named inventor on the platform's core patents and the original architect of the Company's epigenetics underwriting platform. Jon is the founder of FOXO's predecessor entity, and served as the Company's chief executive officer through 2022.

In connection with the Agreement, LFP will pay FOXO a royalty of three percent (3%) of LFP's net revenues, subject to an aggregate cap of $1.3 million. In addition, LFP has been granted an option, exercisable within ten (10) years, to acquire majority ownership of the Company's subsidiary, FOXO Labs, Inc. ("FOXO Labs"). FOXO Labs owns substantially all of the Company's epigenetics-related intellectual property, including the Company's two issued patents, pending applications, proprietary datasets and models, and related intellectual property. The option if exercised, will provide FOXO with a 40% equity interest in the resulting epigenetics enterprise, as defined in the Agreement. The agreement resolves all prior matters between the parties and creates an opportunity to commercialize the technology and create value.

Mr. Sabes has expertise in modernizing the archaic underwriting process used by the life insurance industry, which still requires blood and urine specimen collection for the sale of its permanent life insurance products. He believes the epigenetics technology can replace the existing high-volume invasive diagnostics with a modern non-invasive alternative.

**FOXO Benefits**

● Revitalized effort to commercialize its epigenetic technology

● Royalty stream from LFP

● Upside through a 40% equity interest in the resulting epigenetics enterprise

● Allows FOXO senior management to focus on its core healthcare services operations

**LFP Benefits**

● Reunion of the technology platform with its inventor and original architect

● Commercialization with advanced AI and recent research validating the predictive power of epigenetic biomarkers

● Exclusive, worldwide, rights to commercialize a validated and patented epigenetics technology

● Renewed commercial opportunity driven by advances in artificial intelligences

Seamus Lagan, Chief Executive Officer of FOXO, explained, "We are excited to join forces with former FOXO CEO, Jon Sabes. FOXO's epigenetics technology has not been commercialized over the last few years under the FOXO Technologies Inc. corporate structure. By entering into this agreement with Sabes the technology is being reunited with its visionary and founder, creating a practical pathway to unlock value from the technology while materially improving the Company's financial and strategic position."

"I am thrilled to be reunited with this pioneering technology, on which I am the named inventor and co-creator on U.S. Patent Nos. 11,795,495 and 11,817,214. Recent advances in artificial intelligence, combined with newly published research demonstrating the predictive power of epigenetic DNA methylation patterns as biomarkers of biological aging, have strengthened the original business case on which FOXO was founded. I am grateful for the opportunity and committed to working diligently to create value for FOXO and its stockholders." stated Jon R. Sabes, Managing Member of LongevityFP Technologies, LLC.

**About FOXO Technologies Inc. ("FOXO")**

FOXO owns and operates four key subsidiaries.

Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital in East Tennessee.

Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for medically supervised withdrawal treatment and residential treatment and outpatient services for MAT and OBOT programs.

Vector BioSource, Inc. is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries.

FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.

For more information about FOXO, visit www.foxotechnologies.com. The Company will file a Current Report on Form 8-K with the Securities and Exchange Commission containing additional information about the partnership and the strategic technology license agreement.

**About LongevityFP Technologies, LLC ("LFP")**

LongevityFP Technologies, LLC was formed to commercialize advanced epigenetic underwriting technology for the life insurance industry. Jon R. Sabes serves as Chief Executive Officer.

**Forward-Looking Statements**

This press release is jointly issued by FOXO Technologies Inc. and LongevityFP Technologies, LLC, and contains forward-looking statements made by, or attributable to, each of them. Forward-looking statements include those that use words such as "expects," "anticipates," "believes," "intends," "plans," "projects," "estimates," "may," "will," "should," "could," or similar expressions. These statements are not historical facts, including statements about FOXO's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO's business; the ability to implement FOXO's business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; the enforceability of FOXO's intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO's most recent reports on Forms 10-K and 10-Q, particularly the "Risk Factors" sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

**Contact:**

FOXO Technologies Inc.

Sebastien Sainsbury

ssainsbury@foxotechnologies.com

(561) 485-0151

LongevityFP Technologies, LLC

Jon Sabes

<u>jsabes@longevityfp.com</u>

(612) 388-2223